✦ LIBER ✦

The safety and tolerability of donepezil in patients with Alzheimer's disease

✍ Scribed by Stephen Jackson; Richard J. Ham; David Wilkinson

Book ID: 108640096
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 103 KB
Volume: 58
Category: Article
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.2004.01848.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Donepezil in patients with severe alzhei

Donepezil in patients with severe alzheimer’s disease

✍ Karen Marder 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 61 KB

Tolerability of switching from donepezil

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease

✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving

Long-term donepezil treatment in patient

Long-term donepezil treatment in patients with Alzheimer’s disease

✍ Andrew Kertesz 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 47 KB

Verbal repetition in patients with Alzhe

Verbal repetition in patients with Alzheimer's disease who receive donepezil

✍ Elissa Asp; France Cloutier; Sherri Fay; Cheryl Cook; Mary Lou Robertson; John F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

## Background: Current outcome measures for alzheimer's disease (ad) drugs have been criticized as insufficiently patient-centred. one commonly unmeasured goal of patients and caregivers is verbal repetition. ## Objectives: We examined how often reducing repetition (of questions, statements or st

Efficacy and safety of donepezil over 3

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease

✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##

Preliminary communication: Urodynamic as

Preliminary communication: Urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease

✍ Ryuji Sakakibara; Tomoyuki Uchiyama; Mitsuharu Yoshiyama; Tomoyuki Yamanishi; Ta 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB

## Abstract ## Background and Aims Donepezil hydrochloride, a central cholinergic drug, is widely used for improving cognitive decline in Alzheimer's disease (AD). We investigated whether donepezil might affect the lower urinary tract (LUT) function in AD. ## Methods Alzheimer's Disease Assessme